In patients with sepsis-related immunosuppression, addressing PD-1 and/or PD-L1 appears to be an option with potential clinical benefit, especially since checkpoint inhibitors have already been successfully used in cancer immunotherapy (208). Here, PDCD1 is linked to Sepsis.